A Collaboration Between INRS and NMX Research and Solutions that Accelerates Drug Discovery

Although Fragment-Based Lead Discovery (FBLD) is one of the most promising strategies for discovering future medical compounds, there are still until today barriers that discourage industry from pursuing this approach.

NewsGuest UserNovember 9, 2022BIOOQuébecbiotechnology, NACFC, Laurent Pharmaceuticals, Cystic Fibrosis

Laurent Pharmaceuticals Presents Results from Phase 2 Clinical Study of LAU-7b in Cystic Fibrosis at the NACFC 2022

Laurent Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing LAU-7b (oral fenretinide) as a first-in-class inflammation-controlling drug candidate for Cystic Fibrosis (CF), announces the presentation of results from its placebo-controlled Phase 2 APPLAUD 24-week clinical study in adults with CF at the North American Cystic Fibrosis Conference (NACFC) currently held in Philadelphia, United States.

NewsGuest UserNovember 8, 2022BIOOQuébecbiotechnology, NACFC, Laurent Pharmaceuticals, Cystic Fibrosis

Laurent Pharmaceuticals Starts Phase 3 Study With Once-a-Day Oral COVID-19 Antiviral Treatment Candidate in Hospitalized Moderate-to-Severe Patients

Following the positive outcome of a meeting with the FDA, a first patient was recruited in the Phase 3 expansion of the RESOLUTION study with LAU-7b in hospitalized moderate-to-severe COVID-19 patients

NewsGuest UserFebruary 21, 2022Laurent Pharmaceuticals, COVID-19

Laurent Pharmaceuticals Extends COVID-19 Phase 2 Study with Oral Antiviral LAU-7b that has Showed 100% Reduction in the Risk of Progression onto Mechanical Ventilation and Death

MONTREAL--(BUSINESS WIRE)--Laurent Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (“FDA”) has allowed the Phase 2 RESOLUTION study extension in hospitalized moderate-to-severe adult COVID-19 patients and the change of the primary endpoint to “proportion of patients requiring mechanical ventilation and/or death by Day 60.” The company also announced that the FDA has granted a Type B meeting request to discuss, among other topics, the eligibility to Emergency Use Authorization (EUA) and Phase 3 clinical trials with LAU-7b in COVID-19, in both hospitalized and ambulatory settings. The meeting will take place on January 14th, 2022, via conference call.

NewsGuest UserDecember 15, 2021Laurent Pharmaceuticals, COVID-19

Molecular Forecaster Continues Quest to Fast Track Drug Discovery with Two New Public-Private Partnerships

Molecular Forecaster Inc. (MFI) is excited to announce it has secured funding to further develop its structure-based drug-design software, offer its research services, and expand into new niche drug targets.

NewsGuest UserOctober 1, 2021Laurent Pharmaceuticals, COVID-19, results

Laurent Pharmaceuticals Announces Topline Results from its Phase 2 RESOLUTION Clinical Trial of LAU-7b for the Treatment of COVID-19

Laurent Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing LAU-7b, a first-in-class pro-resolving drug candidate, reported today topline results from its Phase 2 RESOLUTION clinical trial in hospitalized COVID-19 patients.

NewsGuest UserOctober 1, 2021Laurent Pharmaceuticals, COVID-19, results

Laurent Pharmaceuticals Completes Patients Enrollment in Phase 2 Study of LAU-7b for the Treatment of COVID-19

Laurent Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing the first-in-class pro-resolving drug LAU-7b, today announces that it has completed the enrollment for its placebo-controlled Phase 2 RESOLUTION clinical study of hospitalized patients with COVID-19. The study, which enrolled 240 patients across Canada and United States, is expected to report top-line results in Q3 2021.

NewsGuest UserMay 20, 2021Laurent Pharmaceuticals, Phase 2 Study, COVID-19

Laurent Pharmaceuticals Provides Clinical Development Update

MONTREAL, April 8, 2021 /CNW Telbec/ - Laurent Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing first-in-class pro-resolving drug LAU-7b, today announces that the independent Data Safety Monitoring Board (DSMB) for the Phase 2 RESOLUTION study in hospitalized patients with COVID-19 unanimously recommended to continue the study without modification following a pre-scheduled safety review and mid-study interim futility analysis of unblinded efficacy data from the first 102 patients treated in the study. The company also reports the completion of enrollment in its Phase 2 APPLAUD study in adult patients with Cystic Fibrosis (CF).

NewsGuest UserApril 8, 2021COVID-19, Laurent Pharmaceuticals, treatment

Laurent Pharmaceuticals Joins Battle Against COVID-19

Laurent Pharmaceuticals Inc., a clinical-stage biopharmaceutical company that spun off from McGill University in 2012, today announces that it is planning to test its lead drug LAU-7b in patients with COVID-19 disease, as part of a Phase 2 clinical trial.

Laurent Pharmaceuticals Receives a CAD 2.7M Financing from BioMed Propulsion Fund

Laurent Pharmaceuticals Inc. (the “Company”), a biopharmaceutical company focusing on rare diseases, today announced that it has received the final approval for a CAD 2.7M loan from the Quebec Government through its BioMed Propulsion program. This financing will help support the Company’s Phase 2 clinical study evaluating LAU-7b in adult patients with cystic fibrosis (“CF”).